
Ola Caster

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3477095/publications.pdf Version: 2024-02-01



OLA CASTED

#	Article	IF	CITATIONS
1	Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations. Drug Safety, 2020, 43, 479-487.	3.2	60
2	Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADR. Drug Safety, 2019, 42, 1393-1407.	3.2	60
3	Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine, 2019, 17, 100188.	7.1	113
4	Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a global database. British Journal of Clinical Pharmacology, 2018, 84, 1514-1524.	2.4	15
5	Benefit-Risk Assessment in Pharmacovigilance. Methods in Pharmacology and Toxicology, 2018, , 233-257.	0.2	1
6	Characteristics, Quality and Contribution to Signal Detection of Spontaneous Reports of Adverse Drug Reactions Via the WEB-RADR Mobile Application: A Descriptive Cross-Sectional Study. Drug Safety, 2018, 41, 969-978.	3.2	19
7	Assessment of the Utility of Social Media for Broad-Ranging Statistical Signal Detection in Pharmacovigilance: Results from the WEB-RADR Project. Drug Safety, 2018, 41, 1355-1369.	3.2	47
8	<scp>vigiRank</scp> for statistical signal detection in pharmacovigilance: First results from prospective realâ€world use. Pharmacoepidemiology and Drug Safety, 2017, 26, 1006-1010.	1.9	28
9	Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®. Drug Safety, 2017, 40, 81-90.	3.2	80
10	Cheminformatics-aided pharmacovigilance: application to Stevens-Johnson Syndrome. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 968-978.	4.4	13
11	Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses. BMC Neurology, 2015, 15, 206.	1.8	10
12	Authors' Reply to Harpaz et al. Comment on: "Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance― Drug Safety, 2015, 38, 115-116.	3.2	3
13	Implementing Second-Order Decision Analysis: Concepts, Algorithms, and Tool. Advances in Decision Sciences, 2014, 2014, 1-8.	1.2	1
14	Computing limits on medicine risks based on collections of individual case reports. Theoretical Biology and Medical Modelling, 2014, 11, 15.	2.1	3
15	Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance. European Journal of Clinical Pharmacology, 2014, 70, 501-503.	1.9	15
16	Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance. Drug Safety, 2014, 37, 655-659.	3.2	36
17	Improved Statistical Signal Detection in Pharmacovigilance by Combining Multiple Strength-of-Evidence Aspects in vigiRank. Drug Safety, 2014, 37, 617-628.	3.2	83
18	The Development and Evaluation of Triage Algorithms for Early Discovery of Adverse Drug Interactions. Drug Safety, 2013, 36, 371-388.	3.2	27

OLA CASTER

#	Article	IF	CITATIONS
19	Logistic Regression in Signal Detection: Another Piece Added to the Puzzle. Clinical Pharmacology and Therapeutics, 2013, 94, 312-312.	4.7	16
20	Quantitative Benefit-Risk Assessment Using Only Qualitative Information on Utilities. Medical Decision Making, 2012, 32, E1-E15.	2.4	31
21	Dose Variations Associated with Formulations of NSAID Prescriptions for Children. Drug Safety, 2011, 34, 307-317.	3.2	5
22	Reporting Patterns Indicative of Adverse Drug Interactions. Drug Safety, 2011, 34, 253-266.	3.2	24
23	Earlier discovery of pregabalin's dependence potential might have been possible. European Journal of Clinical Pharmacology, 2011, 67, 319-320.	1.9	34
24	Largeâ€scale regressionâ€based pattern discovery: The example of screening the WHO global drug safety database. Statistical Analysis and Data Mining, 2010, 3, 197-208.	2.8	53
25	Reflections on Attribution and Decisions in Pharmacovigilance. Drug Safety, 2010, 33, 805-809.	3.2	9
26	The lasso—a novel method for predictive covariate model building in nonlinear mixed effects models. Journal of Pharmacokinetics and Pharmacodynamics, 2007, 34, 485-517.	1.8	60